Discontinuing antidepressant treatment in major depression

Harvard Review of Psychiatry

Volumn 5, Issue 6, 1998, Pages 293-306

  Viguera, Adele C ^a,b,c   Baldessarini, Ross J ^a,b   Friedberg, Jonathan ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; IMIPRAMINE; LITHIUM; MAPROTILINE; MIANSERIN; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIMELDINE;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW;

EID: 0031895411     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229809003578     Document Type: Review

References (57)

1. Burton R. The anatomy of melancholy. London: Grips & Lloyd, 1652.
2. Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41:949-58.
3. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
4. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-9.
5. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. Long-term outcome of episodes of major depression: clinical and public health significance. JAMA 1984;252:788-92.
6. Angst J. How recurrent and predictable is depressive illness? In: Montgomery SA, Rouillon F, eds. Long-term treatment of depression. New York: Wiley, 1992:1-13.
7. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-18.
8. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993;7:191-5.
9. Black DW, Winokur G, Nasrallah A. Treatment and outcome in secondary depression: a naturalistic study of 1087 patients. J Clin Psychiatry 1987;48:438-41.
10. Keller MB, Lavori PW, Klerman GL, Andreasen NC, Endicott J, Coryell W, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986;43:458-66.
11. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM Jr, Gross LS. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990;51(6 suppl):60-9.
12. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Depression: a neglected major illness. J Clin Psychiatry 1993;54:419-24.
13. Hirschfield RMA, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-40.
14. Gram LF. Fluoxetine. N Engl J Med 1994;331:1354-61.
15. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antimanic and antidepressant agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's the pharmacologic basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:431-59.
16. Baldessarini RJ, Tohen M. Is there a long-term protective effect of mood-altering agents in unipolar depressive disorder? In: Casey DE, Christensen AV, eds. Psychopharmacology: current trends. Berlin: Springer, 1988:130-9.
17. Kupfer DJ. Maintenance treatment in recurrent depression: current and future directions. Br J Psychiatry 1992;161:309-16.
18. Montgomery SA, Montgomery DB. Prophylactic treatment in recurrent unipolar depression. In: Montgomery SA, Rouillon F, eds. Long-term treatment of depression. New York: Wiley, 1992:53-79.
19. United States Depression Guideline Panel. Depression in primary care, vol 2: Treatment of major depression. Rockville, Maryland: US Public Health Service Agency for Health Care Policy and Research, 1993.
20. Prien FR, Kocsis JH. Long-term treatment of mood disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:1067-79.
21. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-8.
22. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:189-92.
23. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993;50:-448-55.
24. Suppes T, Baldessarini RJ, Faedda GL, Tondo, L, Tohen M. Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harvard Rev Psychiatry 1993;1:131-44.
25. Baldessarini RJ, Tondo L, Faedda GL, Suppes TR, Floris G, Rudas N. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996;57:441-8.
26. Baldessarini RJ, Tondo L, Floris G, Rudas N. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Am J Psychiatry 1997;154:551-3.
27. Viguera AC, Baldessarini RJ, Hegarty JD, Van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54:49-55.
28. Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. Am J Ther 1996;3:492-6.
29. Suppes T, Baldessarini RJ, Motohashi N, Tondo L, Viguera A. Risks of discontinuing maintenance treatment with psychotropic medicines. In: Rush J, ed. Modern problems of pharmacopsychiatry. Basel: Karger [In press].
30. Mindham RHS, Rowland C, Shepherd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 1973;3:5-17.
31. Klerman GL, DiMascio A, Weissman M, Prusoff B, Paykel ES. Treatment of depression by drugs and psychotherapy. Am J Psychiatry 1974;131:186-91.
32. Coppen A, Ghose K, Montgomery S, Rao VAR, Bailey J, Jorgensen A. Continuation therapy with amitriptyline in depression. Br J Psychiatry 1978;133:28-33.
33. Stein MK, Rickels K, Weise CC. Maintenance therapy with amitriptyline: a controlled trial. Am J Psychiatry 1980;137:370-1.
34. Van Praag H, De Haan S. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 1980;3:75-83.
35. Bialos D, Giller E, Jatlow P, Docherty J, Harkness L. Recurrence of depression after discontinuation of long-term amitriptyline treatment. Am J Psychiatry 1982;139:325-9.
36. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982;39:1065-9.
37. Björk K. The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders - a double-blind placebo-controlled study. Acta Psychiatr Scand Suppl 1983;308:182-9.
38. Davidson J, Raft D. Use of phenelzine in continuation therapy. Neuropsychobiology 1984;11:191-4.
39. Glen AIM, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychol Med 1984;14:37-50.
40. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-104.
41. Cook BL, Helms PM, Smith RE, Tsai M. Unipolar depression in the elderly: recurrence on discontinuation of tricyclic antidepressants. J Affect Disord 1986;10:91-4.
42. Harrison W, Rabkin J, Stewart JW, McGrath PJ, Tricamo E, Quitkin F. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 1986;47:346-9.
43. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153(suppl 3):69-76.
44. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989;46:783-6.
45. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-9.
46. Eric L. A prospective, double-blind, comparative, multicentre study of paroxetine and placebo in preventing recurrent major depressive episodes [Abstract]. Biol Psychiatry 1991;29(11 suppl):254S-5S.
47. Robinson DS, Lerfald SC, Bennett B, Laux D, Devereaux E, Kayser A, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 1991;27:31-9.
48. Rouillon F, Serrurier D, Miller HD, Gerard MJ. Prophylactic efficacy of maprotiline on unipolar depression relapse. J Clin Psychiatry 1991;52:423-31.
49. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-22.
50. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-73.
51. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992;149:795-800.
52. Old Age Depression Interest Group. How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. Br J Psychiatry 1993;162:175-82.
53. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-95.
54. Kishimoto A, Mizukawa R, Matsuzaki F, Hazama H, Kamase H, Tanaka K, et al. Prophylactic effect of mianserin on recurrent depression. Acta Psychiatr Scand 1994;89:46-51.
55. Kocsis JH, Friedman RA, Markowitz JC, Leon AC, Miller NL, Gniwesch L, et al. Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry 1996;53:769-74.
56. Stewart JW, Tricamo E, McGrath PJ, Quitkin FM. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Am J Psychiatry 1997;154:31-6.
57. Tondo L, Baldessarini RJ, Floris G, Rudas N. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Am J Psychiatry 1997;154:548-50.